Stay updated on ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial
Sign up to get notified when there's something new on the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page.

Latest updates to the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page
- Check4 days agoChange DetectedUpdates the revision/version indicator shown on the page (from “v3.5.2” to “v3.5.3”) with no visible change to the study record content.SummaryDifference0.1%

- Check12 days agoChange DetectedAdded Revision: v3.5.2; Removed Revision: v3.5.0.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check40 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page history.SummaryDifference0.1%

- Check48 days agoChange DetectedNew revision v3.4.3 was added to the history and revision v3.4.2 was removed.SummaryDifference0.1%

- Check69 days agoChange DetectedA new history entry on 2026-02-18 updates the Study Status. The 2026-01-12 version was removed from the history.SummaryDifference0.3%

- Check76 days agoChange DetectedAdded a new revision entry (v3.4.2) to the study record history. The notice about government funding status and the older revision entry (v3.4.1) were removed.SummaryDifference0.7%

Stay in the know with updates to ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page.